Here is what we have for you to keep imagination going as sweltering heat sitson much of the northern hemisphere: drugs developed more than 50 years ago in France and Japan are now claimed for attention deficit disorder and urination problems, respectively; claims concerning rapamycin for schizophreniacome from China; a meloxicam-releasing contraception device has been developed in Chile; and work...

So Mr. Edward Snowden is sitting somewhere in the transit area of Moscow's Sheremetyevo airport, and whenever he is not being debriefed by Mr. Putin's intelligence agents he talks to journalists, releasing bits and pieces of what he knows in a professionally orchestrated sequence.And scores of citizens who now learn the extent and (some) details of the strategic communication surveillance and data...

Once again, we have selected a few goodies for those who are interested in the patenting aspects of drug repurposing, or who simply appreciate a bit of early warningfrom this arena. This issue's highlight probably is Sanofi going after Vertex/J&J's and Merck's HCV protease inhibitors, telepravir and boceprevir, claiming them for cardiorenal disorders. We also like Bayers idea of suggesting the...

OK Ladies & Gentlemen, we haven't blogged since mid-March. But no, H.M. Pharma Consultancy has not folded or been taken over. The entire team is fine, and we are going strong - even stronger than before actually, and this means that at some times we must prioritize our limited capacities. Even so, we have been keeping track of interesting drug repurposing patent applications that were publishe...

Here at H.M. Pharma Consultancy few things make us sigh more than getting the notorious "404 - Page not found" error code displayed -- which means that the server is responding but the link clicked to reach a specific page leads to nowhere. "301 - Moved Permanently" or "410 - Gone" are slightly more informative but rarely used (and the frustration is the same anyway). And of course there are the a...

Slow time in drug repurposing on all fronts; but we did manage to identify a few patent applications that were published during the üast few weeks. - Enjoy and peruse... And remember that H.M. Pharma Consultancy can assist you with all projects related to drug repurpoising.Tarenflurbil: Alzheimer's Disease (failed) →DermatitisIn contrast to its (S)-isomer (R)-flurbiprofen (tarenflurbil; (R)-2-(2-f...

Here we go again with a selection of five recent international patent applications that involve drug repurposing. We at H.M. Pharma Consultancy are as happy as ever to see the attention this service to the public is attracting. - Follow @hmpharmaconon Twitter to receive updates on our non-confidential activities, and on what we simply find interesting. Or check our Google+ corporate page (and incl...

The H.M. Pharma Consultancy Blog: PageviewsThank you all so much for your attention in 2012! This year is now in the history books and certainly some will be happier to see it there than others... But it was a great year for H.M. Pharma Consultancy! And we are particularly happy to show you that this blog has begun to attract some attention, perhaps even to make an impact. The year-over-year devel...

Happy Holidays to all of you! - Yes, this takes us beyond the End Of The World / Rapture / Second Coming (nutheads, insert your favorite choice here). And we DO believe that December 21, 2012 WILL see a significant event, the same one as every year around this time: the winter solstice, a.k.a. Return Of The Light as of old Celtic, Germanic, etc. tradition is definitely going to happen. (Not a...

Attracting more and more customers who entrust us with ever more work and responsibility is excellent for our business but it cuts down on the time we can spend on writing blog posts such as this one. Sorry for that -- the upside is of course that it means that we can sustain a profitable business & go on doing other things, so please stay tuned -- we will continue to share information (and so...